Taxane-Induced Peripheral Neuropathy: Current Management and Emerging Therapeutic Strategies—An Evidence-Based Narrative Review
SN Comprehensive Clinical Medicine · 20.10.2026 · 8 (1)
DOI: 10.1007/s42399-026-02817-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 20.10.2026. Verfasst von Ami Patel und 5 weiteren Autor:innen. Die Arbeit nennt 88 Literaturangaben.
Abstract (Originalsprache)
Purpose
Taxane-induced peripheral neuropathy (TIPN) is a frequent and clinically important complication of taxane-based chemotherapy that can impair sensory function, quality of life, and continuation of anticancer treatment. This narrative review aimed to summarize current evidence on the mechanisms, risk factors, clinical assessment, management, and emerging therapeutic strategies for TIPN.
Methods
A narrative literature search was conducted using PubMed and Scopus, focusing on evidence related to TIPN associated with paclitaxel, docetaxel, and nab-paclitaxel. Recent literature was prioritized, while relevant landmark studies, clinical guidelines, randomized controlled trials, systematic reviews, meta-analyses, observational studies, and mechanistic studies were also considered.
Results
Taxanes cause peripheral nerve injury through multiple interconnected mechanisms, including microtubule stabilization, impaired axonal transport, mitochondrial dysfunction, oxidative stress, neuroinflammation, ion-channel alterations, and neuronal hyperexcitability. The risk and severity of TIPN are influenced by patient-, treatment-, comorbidity-, medication-, lifestyle-, and genetic-related factors. Clinical assessment integrates patient history, neurological examination, clinician-reported toxicity grading, patient-reported outcomes, and objective investigations when clinically indicated. Current evidence does not support routine pharmacological prevention of chemotherapy-induced peripheral neuropathy. Duloxetine has the strongest evidence for the treatment of established painful CIPN, whereas evidence for gabapentinoids, tricyclic antidepressants, combination therapies, and several emerging interventions remains limited or inconsistent. Non-pharmacological approaches and emerging therapies, including vitamin D, mitochondrial-targeted strategies, sodium-channel modulation, stem-cell-based approaches, and nanotechnology-based drug delivery, are also discussed.
Conclusion
TIPN remains a clinically important complication of taxane therapy with limited established treatment options. Early recognition, appropriate symptom assessment, individualized management, and consideration of chemotherapy modification when clinically indicated are important. Further well-designed clinical trials are needed to establish effective preventive and therapeutic strategies for TIPN.
Zitieren
APA
Patel, A., Anand, I. S., Trivedi, N., Shah, J., Patel, S., & Oza, S. (2026). Taxane-Induced Peripheral Neuropathy: Current Management and Emerging Therapeutic Strategies—An Evidence-Based Narrative Review. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02817-7
Vancouver
Patel A, Anand IS, Trivedi N, Shah J, Patel S, Oza S. Taxane-Induced Peripheral Neuropathy: Current Management and Emerging Therapeutic Strategies—An Evidence-Based Narrative Review. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02817-7
BibTeX
@article{Patel2026,
author = {Patel, Ami and Anand, Indermeet Singh and Trivedi, Nirali and Shah, Jigna and Patel, Sandip and Oza, Sweety},
title = {Taxane-Induced Peripheral Neuropathy: Current Management and Emerging Therapeutic Strategies—An Evidence-Based Narrative Review},
journal = {SN Comprehensive Clinical Medicine},
year = {2026},
volume = {8},
number = {1},
doi = {10.1007/s42399-026-02817-7}
}
EUVIMED